Hostname: page-component-8448b6f56d-qsmjn Total loading time: 0 Render date: 2024-04-24T13:23:45.376Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacodynamics of rocuronium 0.3 mg kg−1 in adult patients with and without renal failure

Published online by Cambridge University Press:  25 November 2005

E. N. Robertson ,
J. J. Driessen ,
M. Vogt ,
H. De Boer  and
G. J. Scheffer
E. N. Robertson
Affiliation:
Radboud University, Department of Anesthesia, Nijmegen, The Netherlands
J. J. Driessen
Affiliation:
Radboud University, Department of Anesthesia, Nijmegen, The Netherlands
M. Vogt
Affiliation:
Radboud University, Department of Anesthesia, Nijmegen, The Netherlands
H. De Boer
Affiliation:
Radboud University, Department of Anesthesia, Nijmegen, The Netherlands
G. J. Scheffer
Affiliation:
Radboud University, Department of Anesthesia, Nijmegen, The Netherlands
Get access

Extract

Summary

Background and aim: The neuromuscular effects of a bolus dose of rocuronium 0.6 mg kg−1 under propofol anaesthesia in renal failure patients are prolonged compared to healthy patients. The present study aims to describe the neuromuscular effects of 0.3 mg kg−1 rocuronium under propofol anaesthesia in patients with renal failure and to compare these effects with healthy control patients. Methods: With institutional approval and informed consent, 18 healthy patients and 18 patients with renal failure took part in this prospective open label study. The renal failure patients were undergoing either renal transplantation or insertion of a shunt. Rocuronium 0.3 mg kg−1 was given intravenously after induction of anaesthesia with propofol 1–2 mg kg−1 and fentanyl 2 μg kg−1. Propofol 6–12 mg kg−1 h−1 was used for maintenance of anaesthesia. Four acceleromyographic responses of the thumb after supramaximal stimulation of the ulnar nerve using surface electrodes at 2 Hz every 15 s were measured and recorded. The onset time, the time to recovery of the first twitch to 25% recovery and the time to a train-of-four ratio of 0.7 were all recorded. Wilcoxon rank sum testing was used to compare the pharmacodynamics and to see if medication, gender or electrolytes influenced the duration of the block. P < 0.05 was significant. Results: No statistical differences were seen in the neuromuscular blocking effects of rocuronium between the two groups but there was a significant difference (P < 0.00001) in the variability of the total duration of the block. Conclusions: Rocuronium 0.3 mg kg−1 is suitable for use in patients with renal failure when endotracheal intubation and neuromuscular block for a short period of time are needed. Tracheal intubation is facilitated within 4 min and the block can be antagonized within 20 min.

Keywords

KIDNEY FAILURE CHRONICNEUROMUSCULAR BLOCKING AGENTS, rocuroniumANAESTHETICS INTRAVENOUS, propofolNEUROMUSCULAR BLOCKADE, monitoring
Type
Original Article
Information
European Journal of Anaesthesiology , Volume 22 , Issue 12 , December 2005 , pp. 929 - 932
Copyright
© 2005 European Society of Anaesthesiology

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Robertson EN, Driessen JJ, Booij LHDJ. Pharmacokinetics and pharmacodynamics of rocuronium in patients with and without renal failure. Eur J Anaesth 2005; 22: 4–10.Google Scholar
Khuenl-Brady KS, Pomaroli A, Pühringer F, Mitterschiffthaler G, Koller J. The use of rocuronium in patients with chronic renal failure. Anaesthesia 1993; 48: 873–875.Google Scholar
Cooper RA, Maddineni VR, Mirakhur RK, Wierda JMHK, Brady M, Fitzpatrick KTJ. Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide during isoflurane anaesthesia in patients with and without renal failure. Br J Anaesth 1993; 71: 222–226.Google Scholar
Szenohradsazky J, Fisher DM, Segredo V et al. Pharmacokinetics of rocuronium bromide in patients with normal renal function or patients undergoing cadaver renal transplantation. Anesthesiol 1992; 77: 899–904.Google Scholar
Driessen JJ, Robertson EN, Van Egmond J, Booij LHDJ. Time-course of action of rocuronium 0.3 mg kg−1 in children with and without endstage renal failure. Ped Anesth 2002; 12: 507–510.Google Scholar
Lambalk LM, de Wit APM, Wierda JMKH, Hennis PJ, Agoston S. Dose-response relationship and time course of action of Org 9426. Anaesthesia 1991; 46: 907–911.Google Scholar
Eriksson LI. Evidence-based practice and neuromuscular monitoring and residual curarization: it's time for routine quantitative assessment. Anesthesiology 2003; 98: 1037–1039.Google Scholar
Kopman AF, Zank LM, Ng J, Neumann GG. Antagonism of cisatracurium and rocuronium block at a tactile train-of-four count of 2: Should quantitative assessment of neuromuscular function be mandatory? Anesth Analg 2004; 98: 102–106.Google Scholar
Barclay K, Eggers K, Asai T. Low-dose rocuronium improves conditions for tracheal intubation after induction of anaesthesia with propofol and alfentanil. Br J Anaesth 1997; 78: 92–94.Google Scholar
Prien T, Zahn P, Menges M, Brussel T. 1 × ED90 dose of rocuronium bromide: tracheal intubation conditions and time-course of action. Eur J Anaesthesiol Suppl 1995; 11: 85–90.Google Scholar
Eikermann M, Renzing-Kohler K, Peters J. Probability of acceptable intubation conditions with low dose rocuronium during light sevoflurane anaesthesia in children. Acta Anaesthesiol Scand 2001; 45: 1036–1041.Google Scholar
Miller RN, Sohn YJ, Matteo RS. Enhancement of D-tubocurarine neuromuscular blockade by diuretics in man. Anesthesiology 1976; 45: 442–445.Google Scholar
Durant NN, Nguyen N, Katz RL. Potentiation of neuromuscular blockade by Verapamil. Anesthesiology 1984; 60: 298–303.Google Scholar
Fischer JR, Baer RK. Acute myopathy associated with combined use of corticosteroids and neuromuscular blocking agents. Ann Pharmacother 1996; 30: 1437–1445.Google Scholar